Long-term follow-up of clinical trials of multiple sclerosis therapies
about
M1 and M2 immune activation in Parkinson's Disease: Foe and ally?Application of the 2010 revised criteria for the diagnosis of multiple sclerosis to patients with clinically isolated syndromesOutcome Measures in Clinical Trials for Multiple Sclerosis.Remyelination induced by a DNA aptamer in a mouse model of multiple sclerosis.Observational study assessing demographic, economic and clinical factors associated with access and utilization of health care services of patients with multiple sclerosis under treatment with interferon beta-1b (EXTAVIA).Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the futureReducing selection bias in case-control studies from rare disease registries.Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing-remitting multiple sclerosis?Evaluation of locomotor function and microscopic structure of the spinal cord in a mouse model of experimental autoimmune encephalomyelitis following treatment with syngeneic mesenchymal stem cellsNurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis.Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice.Ion channels in autoimmune neurodegeneration.Rehabilitation interventions in multiple sclerosis: an overview.Immunotherapy of multiple sclerosis: the state of the art.Neurorehabilitation: applied neuroplasticity.An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.The use of multiscale systems biology approaches to facilitate understanding of complex control systems for airway protection.[Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience].White matter and deep gray matter hemodynamic changes in multiple sclerosis patients with clinically isolated syndrome.The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.Cladribine in multiple sclerosis: pitfalls in a new treatment landscape.Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis.Natalizumab may improve cognition and mood in multiple sclerosis.Improving Immunotherapy Through Glycodesign
P2860
Q27024667-26E626E6-29E8-4D90-A9A9-7D9DF52D6FFBQ28295788-8A12E922-9E72-4C4A-BDCB-32206B81D2BBQ31160866-84F25663-8830-41FF-BBF6-1E70B6A40569Q34326301-9524C2B8-D594-4853-A183-EE867BF08F91Q34566243-40E652A8-0736-4049-B9CC-D7E988707CABQ35078327-89AC4C04-CE1B-4542-AAB6-A7CC9A2AADC8Q35439561-F552BA8C-BBE8-49F3-B0C5-C09078D0803EQ36359388-77EAFAF4-498C-4847-A40F-FC0F56C45D4CQ36375008-1A9BA4C7-F7FA-465C-B749-00E0BEE5128AQ37668556-16CEFBCB-E4E0-485A-B80C-9CA5BC661E12Q37684523-E4A25998-B9CE-4799-853F-D12F4C7AF868Q37866428-35ADD71C-64C0-405D-A3D3-554FED7E0229Q38024650-1985F3A1-90A1-4DCF-B285-A181942A9FFDQ38083041-2CD946B6-BA7F-4209-9A3D-0C357E1AC9D4Q38990000-3E3EF594-02FD-4BC3-9CE7-D7F435183851Q42217179-38315008-D734-4EF8-AC68-75F17B0235CEQ42607564-573A8FEB-AF4C-489E-80B2-F4CD91B5FB0FQ45155454-B9DA455C-F7F4-4174-BE75-24419DB299A1Q45324992-6B8E55CE-8989-4F31-88AB-83A3A4FF1654Q45961588-4FC4EE1F-6BDD-4BF8-9BC7-E1628B0E95B8Q46403566-55312688-6A9B-4D60-B4EC-D2C31A91E454Q50065277-789BCDC7-D518-4B08-9BD2-EB2C7876D978Q50593116-0998F43F-B8FD-4BE6-9836-CC0EDD3CD931Q59132146-A26E1D4C-7B25-423D-8255-F12061309F64
P2860
Long-term follow-up of clinical trials of multiple sclerosis therapies
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Long-term follow-up of clinical trials of multiple sclerosis therapies
@ast
Long-term follow-up of clinical trials of multiple sclerosis therapies
@en
Long-term follow-up of clinical trials of multiple sclerosis therapies
@en-gb
Long-term follow-up of clinical trials of multiple sclerosis therapies
@nl
type
label
Long-term follow-up of clinical trials of multiple sclerosis therapies
@ast
Long-term follow-up of clinical trials of multiple sclerosis therapies
@en
Long-term follow-up of clinical trials of multiple sclerosis therapies
@en-gb
Long-term follow-up of clinical trials of multiple sclerosis therapies
@nl
prefLabel
Long-term follow-up of clinical trials of multiple sclerosis therapies
@ast
Long-term follow-up of clinical trials of multiple sclerosis therapies
@en
Long-term follow-up of clinical trials of multiple sclerosis therapies
@en-gb
Long-term follow-up of clinical trials of multiple sclerosis therapies
@nl
P1433
P1476
Long-term follow-up of clinical trials of multiple sclerosis therapies
@en
P2093
M. S. Freedman
P304
P356
10.1212/WNL.0B013E318205051D
P407
P433
1, Supplement 1
P577
2010-12-27T00:00:00Z